遗传性平滑肌瘤病和肾细胞癌（HLRCC）的序贯治疗：病例报告及文献综述
Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature.
作者信息
de Velasco Guillermo, Munoz Cesar, Sepulveda Juan M, Castellano Daniel
机构信息
Department of Uro-Oncology, University Hospital 12 de Octubre, Madrid, Spain.
出版信息
Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E243-6. doi: 10.5489/cuaj.2264.
Abstract
The overall survival for patients with advanced papillary renal carcinoma (RCC) is still limited. Although multikinase inhibitors have recently been developed for clear cell carcinoma, response rates in other histology non-clear cell RCC are poor and patients often face dose-limiting toxicities which lead to a reduction in prognosis and treatment success. We present a patient with hereditary leiomyomatosis and RCC (HLRCC), showing a sustained response for more than 12 months to gemcitabine-bevacizumab therapy after failure tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) therapies.
摘要
晚期乳头状肾细胞癌（RCC）患者的总生存期仍然有限。尽管最近已开发出用于透明细胞癌的多激酶抑制剂，但其他组织学类型的非透明细胞RCC的缓解率较低，患者常面临剂量限制性毒性，这导致预后和治疗成功率降低。我们报告了1例遗传性平滑肌瘤病和肾细胞癌（HLRCC）患者，该患者在酪氨酸激酶抑制剂（TKIs）和雷帕霉素靶蛋白（mTOR）治疗失败后，接受吉西他滨-贝伐单抗治疗，显示出超过12个月的持续缓解。
相似文献
1
Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature.
Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E243-6. doi: 10.5489/cuaj.2264.
2
Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.
BMC Cancer. 2016 Mar 17;16:232. doi: 10.1186/s12885-016-2272-7.
3
Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-Associated Renal Cell Carcinoma Showing High FDG Uptake.
Clin Nucl Med. 2019 May;44(5):420-423. doi: 10.1097/RLU.0000000000002495.
4
Hereditary leiomyomatosis and renal cell carcinoma: Case report and review of the literature.
Urol Ann. 2018 Jan-Mar;10(1):108-110. doi: 10.4103/UA.UA_95_17.
5
Expanding morphological and clinical aspects of hereditary leiomyomatosis and renal cell carcinoma (HLRCC): a case report in a patient with unusual morphology and clinical presentation.
Virchows Arch. 2018 Dec;473(6):775-779. doi: 10.1007/s00428-018-2420-3. Epub 2018 Aug 31.
6
Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
Clin Genet. 2017 Dec;92(6):606-615. doi: 10.1111/cge.13014. Epub 2017 May 2.
7
A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC).
Fam Cancer. 2018 Oct;17(4):615-620. doi: 10.1007/s10689-018-0076-4.
8
Morphologic features of uterine leiomyomas associated with hereditary leiomyomatosis and renal cell carcinoma syndrome: a case report.
Am J Surg Pathol. 2011 Aug;35(8):1235-7. doi: 10.1097/PAS.0b013e318223ca01.
9
Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC): A Contemporary Review and Practical Discussion of the Differential Diagnosis for HLRCC-Associated Renal Cell Carcinoma.
Arch Pathol Lab Med. 2018 Oct;142(10):1202-1215. doi: 10.5858/arpa.2018-0216-RA.
10
Hereditary leiomyomatosis and renal cell cancer (HLRCC).
Curr Mol Med. 2004 Dec;4(8):869-75. doi: 10.2174/1566524043359638.
引用本文的文献
1
Case report: Going through pregnancy safely after twice partial nephrectomy for bilateral kidneys with HLRCC-associated RCC.
Front Oncol. 2022 Oct 18;12:932996. doi: 10.3389/fonc.2022.932996. eCollection 2022.
2
Hereditary Leiomyomatosis and Renal Cell Cancer: Recent Insights Into Mechanisms and Systemic Treatment.
Front Oncol. 2021 May 25;11:686556. doi: 10.3389/fonc.2021.686556. eCollection 2021.
3
A Non-Hereditary Case of Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
Cureus. 2021 Feb 15;13(2):e13344. doi: 10.7759/cureus.13344.
4
Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research.
Semin Cancer Biol. 2020 Apr;61:158-166. doi: 10.1016/j.semcancer.2019.10.016. Epub 2019 Nov 2.
5
Fumarate hydratase in cancer: A multifaceted tumour suppressor.
Semin Cell Dev Biol. 2020 Feb;98:15-25. doi: 10.1016/j.semcdb.2019.05.002. Epub 2019 May 22.
6
Management of Atypical Renal Cell Carcinomas.
Curr Treat Options Oncol. 2017 Sep 14;18(10):61. doi: 10.1007/s11864-017-0501-1.
7
Hereditary leiomyomatosis and renal cell cancer syndrome: identification and clinical characterization of a novel mutation in the FH gene in a Colombian family.
Fam Cancer. 2017 Jan;16(1):117-122. doi: 10.1007/s10689-016-9922-4.
本文引用的文献
1
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2012 Oct;23 Suppl 7:vii65-71. doi: 10.1093/annonc/mds227.
2
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.
Eur Urol. 2012 Dec;62(6):1013-9. doi: 10.1016/j.eururo.2012.06.043. Epub 2012 Jun 27.
3
Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing.
PLoS One. 2012;7(6):e38298. doi: 10.1371/journal.pone.0038298. Epub 2012 Jun 20.
4
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.
Nature. 2011 Jan 27;469(7331):539-42. doi: 10.1038/nature09639. Epub 2011 Jan 19.
5
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.
Invest New Drugs. 2012 Feb;30(1):335-40. doi: 10.1007/s10637-010-9491-6. Epub 2010 Aug 14.
6
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
Am J Clin Oncol. 2011 Apr;34(2):150-4. doi: 10.1097/COC.0b013e3181d6b2fe.
7
Amplification of epidermal growth factor receptor gene in renal cell carcinoma.
Eur J Cancer. 2010 Mar;46(5):859-62. doi: 10.1016/j.ejca.2010.01.011. Epub 2010 Feb 16.
8
LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.
Mol Cancer Ther. 2009 Mar;8(3):626-35. doi: 10.1158/1535-7163.MCT-08-1049. Epub 2009 Mar 10.
9
Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.
Med Oncol. 2009;26(2):202-9. doi: 10.1007/s12032-009-9177-0. Epub 2009 Feb 20.
10
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
J Clin Oncol. 2008 Jan 1;26(1):127-31. doi: 10.1200/JCO.2007.13.3223.
Zotero 插件